



Recent Developments in Cancer Biomarkers for Diagnosis and Prognosis

Guest Editor:

Dr. Raghu Sinha

Department of Molecular and Precision Medicine, Penn State College of Medicine, Penn State Cancer Institute, Penn State Centre for Research on Tobacco and Health, Hershey, PA, USA

Deadline for manuscript submissions:

30 September 2026

Message from the Guest Editor

The biological molecules reflecting the state of initiation and progression in cancer are deemed important biomarkers. These molecules can be measured in tissues, plasma serum saliva, and other biological fluids. Cancer biomarkers are useful not only for early detection but also for monitoring disease progression and treatments. Measuring one biomarker may not be sufficient for all cancer types, and some cancers require a group of biomarkers for accurate diagnosis. These biomarkers could be a combination of tissue and secretory factors. This Special Issue welcomes research articles addressing recent research on experimental, pre-clinical, and clinical cancer biomarkers for diagnosis and prognosis, with a special focus on approaches for discovering novel cancer biomarkers. Biomarkers can include proteins, nucleic acids, metabolites, and more.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory
Medicine and Pathobiology,
Department of Surgery,
University of Toronto, 6 Queens
Pk Crescent W.F, Toronto, ON
M5S 3H2, Canada

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank: CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)